Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zunsemetinib + mFOLFIRINOX in Untreated Metastatic Pancreatic Ductal Adenocarcinoma
NCT06648434Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zunsemetinib in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Recommended phase II dose at 4 weeks and Dose-limiting toxicities at 4 weeks. Started Jun 2025; status: recruiting.
02
Drugs
zunsemetinib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06648434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06648434.